Noorullah O.; Lekharaju V.P.; Din I.U.; Klcova J.; Cross T.; Evans J.; Sturgess R.; Palmer D.; Kumar P.; O’Grady E.; Stern N.; Journal of Hepatology, April 2014,

An external validation of the hepatoma arterial-embolisation prognosis (HAP) score: The Liverpool experience 

Citation: Journal of Hepatology, April 2014, vol./is. 60/1 SUPPL. 1(S401-S402), 0168-8278 (April 2014)

Author(s): Noorullah O.; Lekharaju V.P.; Din I.U.; Klcova J.; Cross T.; Evans J.; Sturgess R.; Palmer D.; Kumar P.; O’Grady E.; Stern N.

Abstract: Background and Aims: Most hepatocellular carcinomas (HCCs) have palliative treatment. Trans-arterial embolisation (TAE) or chemoembolisation (TACE) are used with variable results. The HAP score was recently described to determine patients likely to benefit from
TAE or TACE. We report our experience with TAE and TACE to assess whether the HAP score was valid for our cohort of patients. Methods: Retrospective review of cases given TAE or TACE in Liverpool, UK (2006-2013). HAP score [1 point each for albumin <36 g/dl, AFP >400 ng/ml, bilirubin >17 mumol/l, tumour diameter >7cm. HAP A = 0 points,
B = 1, C = 2, D> 2].

Source: EMBASE

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s